In ArmaGen, Investors Seek A Brain-Penetrating Breakthrough
This article was originally published in Start Up
Executive Summary
For years, traditional VCs passed on ArmaGen’s technology that pulls drugs across the blood-brain barrier to reach previously undruggable targets. But in 2012, a syndicate of corporate investors obliged, suggesting they don’t mind losing their money if they can learn more about a difficult problem.